GE Healthcare, Medtronic Partnership Accelerates Global Access to Personalized Care by Delivering Advanced Patient Monitoring Solutions on the CARESCAPE Platform
GE Healthcare, Medtronicreceive FDA 510(k) clearance and CE Mark approval on the integration of advanced INVOS™ regional oximetry and Microstream™ capnography technologies on the CARESCAPEprecision monitoring platform
- Helping providers improve patient outcomes and safety, Microstream™ capnography (CO2) technology captures evolving respiratory compromise while INVOS™ regional oximetry (rSO2) technology helps clinicians predict and prevent perioperative complications quicker than traditional peripheral measurement1,2
- Integration allows for continuous monitoring access at the bedside, in transport, and networked to the electronic medical record (EMR), helping providers increase efficiency, enhance patient safety, and improve quality of care
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220601005454/en/
“Our longstanding collaboration with Medtronic allows
Since before the inception of the
“Personalizing care to each patient is the standard of care. As providers, we prioritize how care is given based on individual patient acuity, so, when we’re working with a monitoring platform, it is helpful to be able to choose from different parameters to aid in capturing signs of deterioration as quickly as possible,” said Dr.
The INVOS™ regional oximetry (rSO2) technology solution monitors for signs of hemodynamic changes and deteriorating patient conditions associated with cerebral desaturation events. When used as an indication of compromised cerebral oxygenation, INVOS technology can help clinicians return the patient’s rSO2 to baseline and has been shown to improve postoperative outcomes including hospital length of stay, POD, and MOMM.3,4 Patients undergoing on-pump coronary artery bypass grafting (CABG) spent an average of 14 hours less in the ICU when receiving near-infrared spectroscopy-guided care with INVOS™ rSO2.5
The advanced Microstream™ capnography (CO2) technology solution offers clinicians early indication of patient decline1 and is validated for neonate to adult patients. It uses a proprietary CO2-specific infrared wavelength that is highly accurate and unaffected by the presence of other gases. The technology also features Smart Capnography™ algorithms engineered to enhance patient safety, improve clinical workflow, and ease alarm fatigue by reducing clinically insignificant nuisance alarms by 53%. This technology potentially cuts down on the high demand placed on providers to respond to non-emergent issues.6
The Microstream™ capnography and INVOS™ monitoring systems should not be used as the sole basis for diagnosis or therapy and are intended only as adjunct in patient assessment.
1Chung F, Wong J, Mestek ML, Niebel KH, Lichtenthal P. Characterization of respiratory compromise and the potential clinical utility of capnography in the post-anesthesia care unit: A blinded observational trial. J Clin Monit Comput.
2Avery, Edwin G. IV, M.D., C.P.I., Cerebral Oximetry is Frequently a “First Alert” indicator of adverse outcomes, Medtronic white paper, 2016.
3Deschamps A, Hall R, Grocott H, et al. Cerebral Oximetry Monitoring to Maintain Normal Cerebral Oxygen Saturation during High-risk Cardiac Surgery: A Randomized Controlled Feasibility Trial. Anesthesiology. 2016;124(4):826-36
4Zorrilla-Vaca A, Healy R, Grant M, et al. Intraoperative cerebral oximetry-based management for optimizing perioperative outcomes: a meta-analysis of randomized controlled trials,
5 Murkin JM, Adams SJ, Novick RJ, et al. Monitoring brain oxygen saturation during coronary bypass surgery: a randomized, prospective study. Anesth Analg. 2007;104(1):51–58.
6Internal test data on file.
About the Patient Monitoring Operating Unit at Medtronic:
With patient safety at our core, the Patient Monitoring business develops technologies that provide clinicians with actionable insights to personalize care. Our solutions will enable clinicians to predict and prevent complications reducing costs and improving outcomes.
Bold thinking. Bolder actions. We are Medtronic.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the